Publications by authors named "Donald Gleason"

Claim this Profile
P
Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical Staging.
Donald F Gleason, George T Mellinger,

J Urol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Fred Saad, Yin-Miao Chen, Donald M Gleason, Joseph Chin

Clin Genitourin Cancer· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup.
David G McLeod, William A See, Ira Klimberg, Donald Gleason, Gerald Chodak

J Urol· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Fred Saad, Donald M Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner

J Natl Cancer Inst· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Peter Iversen, Manfred P Wirth, William A See, David G McLeod, Ira Klimberg, Donald Gleason

Urology· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Matthew R Smith, James Eastham, Donald M Gleason, Daniel Shasha, Simon Tchekmedyian

J Urol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Ramon Perez-Marreno, Franklin M Chu, Donald Gleason, Edward Loizides, Barton Wachs

Clin Ther· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Fred Saad, Donald M Gleason, Robin Murray, Simon Tchekmedyian, Peter Venner

J Natl Cancer Inst· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
William A See, Manfred P Wirth, David G McLeod, Peter Iversen, Ira Klimberg, Donald Gleason

J Urol· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Akhouri A Sinha, Barry J Quast, Michael J Wilson, Eduardo T Fernandes, Pratap K Reddy, Donald F Gleason

Cancer· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. 1974.
Donald F Gleason, George T Mellinger,

J Urol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis